

C<sup>2</sup> 17. (Amended) The kit of claim 15, wherein R<sub>1</sub> is Gln, Lys, or Arg; R<sub>2</sub> is Arg; R<sub>3</sub> is Arg; R<sub>4</sub> is Ala; R<sub>5</sub> is Ala; R<sub>6</sub> is Val; R<sub>7</sub> is Asp; R<sub>8</sub> is Thr; R<sub>9</sub> is Tyr; R<sub>10</sub> is Cys; R<sub>11</sub> is Arg; R<sub>12</sub> is His; R<sub>13</sub> is Asn; R<sub>14</sub> is Tyr; R<sub>15</sub> is Gly, and R<sub>16</sub> is Val (SEQ ID NO:2).

C<sup>3</sup> 21. (Amended) The method of claim 19, wherein R<sub>1</sub> is Gln, Lys, or Arg; R<sub>2</sub> is Arg; R<sub>3</sub> is Arg; R<sub>4</sub> is Ala; R<sub>5</sub> is Ala; R<sub>6</sub> is Val; R<sub>7</sub> is Asp; R<sub>8</sub> is Thr; R<sub>9</sub> is Tyr; R<sub>10</sub> is Cys; R<sub>11</sub> is Arg; R<sub>12</sub> is His; R<sub>13</sub> is Asn; R<sub>14</sub> is Tyr; R<sub>15</sub> is Gly, and R<sub>16</sub> is Val (SEQ ID NO:2).

REMARKS

Claims 7-24 are pending in this application. Claims 9, 17, and 21 have been amended. The amendments to claims 9, 17, and 21 insert the required assigned identifiers for amino acid sequences described in these claims consistent with the same identifiers assigned elsewhere in the Specification.

Entry of the amendments is requested and is appropriate. As noted in the Applicants' Communication dated May 28, 2002, the amendments conform the claims to the identifiers as stated in the remainder of the specification. This Amendment contains no new matter.

For the Examiner's convenience, a copy of all the claims as pending after this Amendment is attached.